Abstract:Platelet activation and aggregation play an important role in the pathological and physiological processes of recurrent ischemic vascular events in stroke patients. The purpose of this study is to determine the association between platelet function measured in the acute period and recurrent ischemic vascular events in patients with transient ischemic attack (TIA) or minor stroke. A total of 417 patients who were within the 24-hour period of clopidogrel-aspirin therapy after onset of a minor stroke or high-risk transient ischemic attack according to the Clopidogrel in High-risk patients with Acute Nondisabling Cerebrovascular Events (CHANCE) trial were included in this study. The platelet aggregation ratio was detected using a method of continuous platelet counting; patients underwent CYP2C19 genotyping, and the baseline data were recorded. The patients underwent a 6-month follow-up period during which the recurrent ischemic vascular events were observed. Logistic regression analysis was performed to obtain the risk factors for recurrent ischemic vascular events. The number of patients with recurrent ischemic events who had an arachidonic acid-induced maximum platelet aggregation ratio (MAR-AA) (aspirin 100 mg) (31.85 +/- 12.86 vs. 26.71 +/- 12.44, p = 0.007) and adenosine diphosphate-induced maximum platelet aggregation ratio (MAR-ADP) after the administration of 75 mg clopidogrel for 12 +/- 2 days (65.82 +/- 10.72 vs. 53.10 +/- 12.98, p < 0.001) was significantly higher compared with the no ischemic vascular event group. Multivariate logistic regression analyses showed that being a carrier of the CYP2C19 loss-of-function (LOF) allele (OR = 2.308, 95% CI: 1.087 similar to 4.901, p = 0.029) as well as the MAR-AA (aspirin 100 mg) (OR = 1.028, 95% CI: 1.006 similar to 1.052, p = 0.014) and MARADP after the administration of 75 mg clopidogrel (OR = 1.067, 95% CI: 1.037 similar to 1.095, p < 0.001) were risk factors for ischemic vascular events. The MAR-ADP after the administration of 75 mg clopidogrel was significantly higher in patients who were carriers of the CYP2C19 (LOF) allele compared with non-carriers (57.53 +/- 13.32 vs. 50.86 +/- 12.55, p < 0.001), and no significant differences between the CYP2C19 LOF allele carriers and non-carriers in the MAR-ADP were detected after the administration of 300 mg clopidogrel (37.18 +/- 11.36 vs. 35.86 +/- 12.49, p = 0.264). Being a carrier of the CYP2C19 LOF allele has a significant influence on clopidogrel response. Platelet function is closely related to recurrent ischemic vascular events in acute minor stroke or TIA patients.

Correlation Between Antiplatelet Resistance and Recurrent Cardiac Ischemic Events of Patients with Acute Myocardial Infarction

Predictive Value of Antiplatelet Resistance on Early Stent Thrombosis in Patients with Acute Coronary Syndrome.

Predictors of Recurrent Angina in Patients with No Need for Secondary Revascularization.

[Clopidogrel Resistance of Patients with Coronary Artery Disease and Its Correlation with Platelet Count and Mean Platelet Volume].

Monitoring Residual Platelet Activity among Patients with Acute Coronary Syndrome.

Clinical analysis of clopidogrel resistance in patients with coronary heart disease after percutaneous coronary intervention

Adequate Platelet Function Inhibition Confirmed by Two Inductive Agents Predicts Lower Recurrence of Ischemic Stroke/Transient Ischemic Attack

The impact of high on-treatment platelet reactivity and fibrinogen levels on ischemic events in patients with ST elevation myocardial infarction: a prospective observational study

The clinical and laboratory research on aspirin resistance in cardiovascular and cerebrovascular patients

Recurrence of ischemic stroke associated high on-treatment platelet reactivity:correlation study

Association Between Platelet Function and Recurrent Ischemic Vascular Events after TIA and Minor Stroke .

Impact of serum lipid level on residual platelet reactivity in patients with non-ST elevation acute coronary syndrome receiving dual anti-platelet therapy after percutaneous coronary intervention

Platelet-fibrin Clot Strength Measured by Thromboelastography Could Predict Hypercoagulability and Antiplatelet Effects in Patients after Percutaneous Coronary Intervention.

Efficacy of predicting thrombotic events with combination of dual point-of-care testing (POCT) after drug-eluting stent implantation for coronary heart disease: results from the CILON-T randomized trial POCT substudy

Comparison of Different Laboratory Tests to Identify "Aspirin Resistance" and Risk of Vascular Events among Ischaemic Stroke Patients: A Double-Blind Study

Analysis of ischemic subtypes and risk factors of recurrence of ischemic stroke patients using antiplatelet drugs

Platelet-large cell ratio predicts no-reflow in patients undergoing primary coronary angioplasty for ST-segment elevation myocardial infarction

Antiplatelet Drugs Resistance after Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome and Chronic Kidney Disease

Multi-parameter Assessment of Platelet Inhibition and Its Stability During Aspirin and Clopidogrel Therapy

Platelet Aggregability as a Predictor of Restenosis Following Carotid Endarterectomy

Thrombus aspiration is associated with improved platelet inhibition rate following dual antiplatelet therapy in acute myocardial infarction patients